Variational AI will participate in ALL IN 2026, Canada’s largest artificial intelligence conference, taking place September 16 and 17, 2026 at the Palais des congrès de Montréal. The event brings together more than 6,500 decision-makers, researchers, founders, and investors from over 40 countries for two days of programming on how AI is moving from research into applied use across sectors of the economy.
Drug discovery is one of the domains where generative AI is now being measured against experimental outcomes rather than benchmarks. Variational AI uses generative AI to design novel, synthesizable small molecules optimized simultaneously across potency, selectivity, ADMET, and synthetic feasibility. Our foundation model, Enki™, covers 873 pretrained targets and extends to proximity-based therapeutics and antibody-drug conjugate payloads.
Who will be there
Handol Kim, Co-Founder & CEO
Valentin Beuchillot, Director of Business Development & Marketing
We will be meeting with AI and life sciences organizations, potential biopharma partners, and investors to discuss where generative molecular design fits into existing discovery programs.
Meet the team
If you are attending ALL IN 2026 and would like to connect, reach out to bd@variational.ai to schedule time.